Prevalence of E. Coli in Urinary Tract Infection of Children Aged 1-15 Years in A Medical College of Eastern Nepal
Introduction: Urinary tract infection is one of the commonest causes of childhood morbidity. Early
diagnosis and appropriate choice of antimicrobials is essential. Hence, this study aims to identify the
prevalence of Escherichia coli in childhood urinary tract infections.
Methods: This was a hospital based descriptive cross-sectional study conducted in Nobel Medical
College, Biratnagar over a period of one year. A total of 163 cases aged 1-15 years were included and
clinical profile, laboratory reports including bacterial isolates in urine cultures and their sensitivity
patterns were documented.
Results: The prevalence of Escherichia coli is 45 (53.57%) C.I. Escherichia coli was the most common
organism isolated in bacterial cultures followed by Klebsiella 12 (14.29%), Enterococcus 10 (11.90%).
Urinary tract infection was common among females with male: female ratio of 1:2.3. Fever 152
(93.2%) and abdominal pain 113 (69.3%) were the most common presenting symptoms. Escherichia
coli was found most sensitive to Nitrofurantoin 43 (95.5%) followed by Ciprofloxacin 41 (91.1%) and
Amikacin 40 (88.8%).
Conclusions: Urinary tract infections in childhood require prompt attention and treatment to prevent
significant morbidity and mortality. From this study it can be concluded that Escherichia coli is one
of the most common isolates in urine culture and Aminoglycosides and Fluoroquinolones can be
accepted as empirical treatment regimens for childhood Urinary tract infections.
Copyright (c) 2020 Arun Giri, Raju Kafle, Ganesh Kumar` Singh, Niraj Niraula
This work is licensed under a Creative Commons Attribution 4.0 International License.
JNMA allow to read, download, copy, distribute, print, search, or link to the full texts of its articles and allow readers to use them for any other lawful purpose. The author(s) are allowed to retain publishing rights without restrictions. The JNMA work is licensed under a Creative Commons Attribution 4.0 International License. More about Copyright Policy.